Morphology & Grade
ICD-O Morphology Codes
If the diagnostic term in the pathology report is not in the list below, be sure to consult your ICD-O manual.
Pancreas
- Adenocarcinoma (81403)
- Mucinous (colloid) carcinoma (84803)
- Duct cell carcinoma (85003; 90% of all cases)
- Islet cell carcinoma (81503; NOS arise in Islets of Langerhans)
- Insulinoma (81513; produce insulin)
- Glucagonoma (81523; produce glucagon)
- Gastrinoma (81533; produce gastrin)
Other histologies
- Wilms tumor (nephroblastoma; 89603)—large bulky tumor of childhood; rare in adults
- Lymphoma (many cell types)
- Sarcoma (many cell types)
- Hemangiopericytoma (91503)
- Cystadenocarcinoma (84403; arise in tail of pancreas)
- Other cell types: papillary cystic carcinoma (84521); adenoacanthoma (85703);
- pancreatoblastoma (89713) and many others
- Mixed islet cell and exocrine adenocarcinoma (81543)
- Lymphomas and sarcomas (many cell types)
Key words
- Apudoma (82481)
- Vipoma tumor producing vasointestinal peptide
Gallbladder
- Adenocarcinoma (81403)
- Subtypes: signet ring cell, clear cell, colloid, oat cell and others
Liver
- Hepatoma (81703; 70-90 % of all primary liver tumors; also called hepatocellular, hepatocarcinoma, or liver cell carcinoma)
- Fibrolamellar hepatocellular carcinoma (81713)
- Combined hepatocellular carcinoma and cholangiocarcinoma (81803)
Ampulla of Vater
- Adenocarcinoma (81403)
Bile Ducts (intra and extrahepatic)
- Cholangiocarcinoma (81603; also called bile duct carcinoma) Klatskin's tumor (81623) Adenocarcinoma (81403; most common for extrahepatic bile duct tumors) Sarcomas (several types)
Synonyms for in situ carcinoma: (adeno)carcinoma in an adenomatous polyp with no invasion of stalk, confined to epithelium, noninfiltrating, intraepithelial, involvement up to but not including the basement membrane, noninvasive, no stromal involvement, papillary noninfiltrating.
Suggested Citation
SEER Training Modules: Morphology & Grade. U.S. National Institutes of Health, National Cancer Institute. Cited 17 January 2026. Available from: https://training.seer.cancer.gov.